Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
Green Dot Corporation (NYSE:GDOT)’s shares picked up 7.89%, and closed at $17.10.
Green Dot Corporation (GDOT), declared that it will take part at the following investor conferences in March:
On Tuesday, March 10th, the Corporation will present at the KBW Cards, Payments & Financial Technology Symposium at the Mandarin Oriental Hotel in New York, NY. The presentation will start at 1:45 PM ET.
On Wednesday, March 11th, the Corporation will host investor meetings at Sanford Bernstein’s 2nd Annual Financials Summit at the Taj Boston in Boston, MA.
On Tuesday, March 24th, the Corporation will host investor meetings at the Barclay’s Emerging Payments Forum at The Westin New York Times Square in New York, NY.
Green Dot Corporation, together with its wholly owned partner, Green Dot Bank, is a pro-consumer financial technology innovator with a mission to reinvent personal banking for the masses. Green Dot invented the prepaid debit card industry and is the largest provider of reloadable prepaid debit cards and cash reload processing services in the United States.
Green Plains Inc (NASDAQ:GPRE), raised 7.84%, and closed at $25.99.
Green Plains Inc. (GPRE), declares that Todd Becker, President and Chief Executive Officer, will present at the 27th Annual ROTH Conference in Dana Point, California on March 9, 2015. Green Plains’ presentation is planned to take place at 3:30 p.m. PT and will be accessible via webcast.
Green Plains Inc. (GPRE) is a diversified commodity-processing business with operations related to ethanol production, corn oil production, grain handling and storage, cattle feedlot operations, and commodity marketing and distribution services.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX), enhanced 7.73%, and closed at $4.04, hitting new 52-week high of $4.05.
Catalyst Pharmaceutical Partners Inc. (CPRX), a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, declared that the U.S. Food and Drug Administration (FDA) has granted the corporation orphan drug designation for Firdapse(TM) for treatment of patients with Congenital Myasthenic Syndromes (CMS).
CMS is a rare neuromuscular disease comprising a spectrum of genetic defects and is characterized by fatigable weakness of skeletal muscles with onset at or shortly after birth or early childhood; in rare cases symptoms may not manifest themselves until later in childhood. The severity and course of the disease are variable, ranging from minor symptoms to progressive disabling weakness; symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency also occur.
Catalyst also confirmed that it has received the formal minutes from the FDA reporting on the discussions at its pre-new drug application (NDA) meeting held earlier this year and that the minutes of the meeting confirm the information about the results of the meeting formerly stated by Catalyst. On February 2, 2015, Catalyst stated that it had held a productive pre-NDA meeting with the FDA regarding Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and that, based on the discussions at that meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse(TM) for LEMS. Catalyst also stated that potential paths forward for one type of congenital myasthenic syndromes were also discussed at the meeting.
Catalyst Pharmaceuticals is a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, counting Lambert-Eaton Myasthenic Syndrome (LEMS), congenital myasthenic syndrome (CMS), infantile spasms, and Tourette Syndrome.
Rigel Pharmaceuticals, Inc (NASDAQ:RIGL), enhanced 7.14%, and closed at $3.30.
Rigel Pharmaceuticals, Inc. (RIGL), stated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel stated a net loss of $22.3 million, or $0.25 per share, contrast to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.
Contract proceeds from collaborations of $8.3 million and $5.8 million in the fourth quarters of 2014 and 2013, respectively, were comprised of non-refundable payments earned from AstraZeneca AB (AZ) as a result of its continued development of R256 in asthma.
Rigel stated total costs and expenses of $30.6 million in the fourth quarter of 2014, contrast to $22.7 million in the fourth quarter of 2013. The raise in costs and expenses was primarily due to a charge related to the loss on executing a sublease during the quarter, in addition to an raise in stock-based compensation expense and severance costs related to the retirement of Rigel’s former chief executive officer, partially offset by the decrease in research and development costs. The loss on the sublease is determined based on the present value of the excess of Rigel’s future remaining payments to its landlord through January 2018 associated with the applicable subleased space over its contractual sublease revenue from its subtenant over the term of the sublease contract Rigel executed in December 2014. The research and development costs in the fourth quarter of 2013 were comprised of certain non-recurring development costs related to the transfer of fostamatinib raw materials from AZ. Research and development costs reduced in 2014 due to the completion of a Phase 2 clinical study with R348 in dry eye and the discontinuation of a Phase 1 clinical study with R118, Rigel’s indirect AMPK activator program.
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development corporation that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
